Donanemab (anti-N3pG Aβ antibody) in Phase II TRAILBLAZER-ALZ reduced amyloid plaque load to near-zero in a majority of participants and slowed clinical decline on the iADRS by 32% versus placebo at 76 weeks in early symptomatic AD.

Evidence span

Donanemab (anti-N3pG Aβ antibody) in Phase II TRAILBLAZER-ALZ reduced amyloid plaque load to near-zero in a majority of participants and slowed clinical decline on the iADRS by 32% versus placebo at 76 weeks in early symptomatic AD.

From Mark A. Mintun et al. 2021, New England Journal of Medicine

Method & conditions

Evidence type

experimental

Method

manual state transition; placebo-controlled clinical trial where source reports control arm

Species

Homo sapiens

Conditions

TRAILBLAZER-ALZ Phase II RCT; n=272 early AD (amyloid+ by PET); donanemab 700mg then 1400mg Q4W vs placebo; primary: iADRS at 76 weeks; amyloid PET centiloid; APOE4 stratified.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required